PROGRAMME

Two days of clinically relevant science

Explore the full scientific programme - from clinical implementation and disease-specific evidence to emerging applications of liquid biopsy and ctDNA.

10-11 NOVEMBER 2026 · UPPSALA, SWEDEN

Programme updated 21 October · Subject to change

DAY 1 · TUESDAY, 10 NOVEMBER

Joint conference day with the European Liquid Biopsy Society

REGISTRATION · Registration open 12.00-15.00

10.00-13.00 · ELBS OPEN SCIENTIFIC SESSION

13.00-14.00 · LUNCH

14.00-15.45 · SESSION 1

WELCOME

Anders Edsjö MD, PhD Deputy director of Genomic Medicine Sweden, Consultant Pathologist, Skåne University Hospital and Lund University, Sweden.

CLINICAL IMPLEMENTATION: CHALLENGES FOR ctDNA TESTS

Klaus Pantel, MD, PhD Professor of Medicine and Director, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany. Founder and Chairman of the European Liquid Biopsy Society.

CIRCULATING TUMOR DNA IN PROSTATE CANCER: FROM RETROSPECTIVE RESEARCH AND THE PROSPECTIVE PROBIO TRIAL TO CLINICAL ROUTINE IMPLEMENTATION

Johan Lindberg, PhD Principal Researcher and Associate Professor (Docent), Karolinska Institutet, Sweden.

RELIABLE MOLECULAR PROFILING OF LOW-ctDNA HGSC

Jaana Oikkonen, PhD Postdoctoral Researcher, University of Helsinki, Finland.

ABSTRACT PRESENTATION

GOLD SPONSOR PRESENTATION · NATERA

SIGNATERA MRD ACROSS TUMOR TYPES: EVIDENCE, CLINICAL APPLICATIONS AND EVOLVING ONCOLOGY PRACTICE

Enrico de Toni International Senior Medical Director, Oncology, at Natera and Professor of Medicine at the University of Munich.

15.45-16.15 · COFFEE AND POSTER MINGLE

16.15-18.00 · SESSION 2

ABSTRACT PRESENTATION

ctDNA/RNA MONITORING IN SARCOMAS AND BEYOND

Anders Ståhlberg, PhD Professor of Molecular Medicine, University of Gothenburg, Sweden. Expert in liquid biopsy technologies, circulating tumor DNA and single-cell analysis.

cfDNA IN ENDOMETRIAL CANCER

Kristina Lindemann, MD, PhD Professor of Gynecologic Oncology and Senior Consultant, University of Oslo and Oslo University Hospital, Norway.

CELL-FREE HPV DNA AS A BIOMARKER IN CERVICAL CANCER

Emma Tham MD, PhD Professor of Clinical Genetics and Senior Consultant Clinical Geneticist, Karolinska Institutet and Karolinska University Hospital, Sweden.

PANEL DISCUSSION

LIQUID BIOPSY - WE CAN MEASURE, BUT HOW LOW DO WE NEED TO GO? SPECIFICITY AND SENSITIVITY

Johan Lindberg, Jaana Oikkonen, Anders Ståhlberg, Kristina Lindemann, Emma Tham

SUMMARY

19.00 · DINNER AT MUSEUM GUSTAVIANUM

DAY 2 · WEDNESDAY, 11 NOVEMBER

REGISTRATION · Registration open 08.30-10.00

09.00-10.30 · SESSION 3

START UP: REVIEW OF YESTERDAY AND TODAY'S FOCUS

CIRCULATING TUMOR DNA FOR DIAGNOSIS AND MONITORING IN B-CELL LYMPHOMAS

Zahra Haider, PhD Researcher, Karolinska Institutet, Sweden.

HOW MIGHT WE DEPLOY LIQUID BIOPSY IN LARGE B-CELL LYMPHOMA

Sirpa Leppä, MD, PhD Professor and Senior Consultant Oncologist, University of Helsinki and Helsinki University Hospital, Finland.

PERSONALIZED ctDNA ANALYSIS FOR DISEASE MONITORING ACROSS CHILDHOOD MALIGNANCIES

Martin Dalin MD, PhD Associate Professor and Research Group Leader, University of Gothenburg and Sahlgrenska University Hospital, Sweden.

ABSTRACT PRESENTATION

10.30-11.00 · COFFEE AND POSTER MINGLE

11.00-12.30 · SESSION 4

FROM RESECTION TO ADJUVANT THERAPY AND RECURRENCE PREDICTION: THE ROLE OF ctDNA IN POST-SURGERY CRC MANAGEMENT

Claus Lindbjerg Andersen, PhD Professor of Translational Cancer Research, Aarhus University, Denmark.

PREDICTING CANCER ONSET IN LYNCH SYNDROME BY LIQUID BIOPSIES (PREDI-LYNCH): STUDY PROTOCOL FOR AN INTERNATIONAL, MULTICENTRE, RANDOMISED CONTROLLED TRIAL

Toni Seppälä, MD, PhD Professor and Colorectal Surgeon, Tampere University and Tampere University Hospital, Finland.

THE CITCCA STUDY - CIRCULATING TUMOUR DNA AS A PROGNOSTIC AND PREDICTIVE MARKER IN COLORECTAL CANCER

Cecilia Merk, MD PhD Student, Department of Molecular Medicine and Surgery, Karolinska Institutet, Sweden.

ctDNA IN THE CLINICAL MANAGEMENT OF MUSCLE INVASIVE BLADDER CANCER

Lars Dyrskjøt, Msc, PhD Professor of Molecular Medicine, Aarhus University and Aarhus University Hospital, Denmark.

12.30-13.30 · LUNCH

13.30-15.00 · SESSION 5

ctDNA TESTING IN CLINICAL PRACTICE IN FRANCE: EXPERIENCE WITH CGP IN GUSTAVE ROUSSY

Etiènne Rouleau, MD, PhD Head of the Genetics Unit, Gustave Roussy Cancer Center, France.

FROM RESEARCH TO PRACTICE; PLASMA 1ST DIAGNOSIS OF LUNG CANCER

Alastair Greystoke, MBBS, PhD Professor of Medical Oncology and Honorary Consultant Medical Oncologist, Newcastle University and Newcastle Hospitals NHS Foundation Trust, UK.

ctDNA IN LUNG CANCER

Maria Planck, MD, PhD Associate Professor and Senior Consultant, Lund University and Skåne University Hospital, Sweden.

ABSTRACT PRESENTATION

15.00-15.30 · COFFEE AND POSTER MINGLE

15.30-17.00 · SESSION 6

BEYOND DETECTION: WHEN SHOULD CTDNA DRIVE TREATMENT IN BREAST CANCER?

Isaac Garcia-Murillas PhD Group Leader, Breast Cancer Liquid Biopsy Laboratory, The Institute of Cancer Research and The Royal Marsden Hospital , London, UK.

ctDNA IN BREAST CANCER (NORDIC)

Lao Saal, MD, PhD Professor of Oncology, Lund University, Sweden. Senior Consultant and translational cancer genomics researcher.

ABSTRACT PRESENTATION

PANEL DISCUSSION

LIQUID BIOPSY - CAN WE ACT ON IT AND HOW DO WE IMPLEMENT?

Sirpa Leppä, Claus Lindbjerg, Alastair Greystoke, Isaac Garcia-Murillas

CLOSING REMARKS

WITH SUPPORT FROM

CANCERFONDEN

This programme has been financially supported by sponsorships from:

GOLD SPONSOR

natera™

SILVER SPONSORS

techtum

NEW ENGLAND Biolabs®

BIO-RAD

SOPHiA GENETICS™

Lilly A MEDICINE COMPANY

rarity BIOSCIENCE

BioNordika

HOLEY INNOVATION THROUGH STRUCTURE

illumina®

AstraZeneca

BRONZE SPONSORS

QIAGEN

Oxford Nanopore Technologies

MSD

WATCHMAKER GENOMICS

TWIST BIOSCIENCE

MENARINI group

Stemline A Menarini Group Company

VISIT OUR WEBSITE

nordicliquidbiopsy.se